Lucid Diagnostics Inc LUCD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.37–0.42
- 52-Week Range
- $0.30–1.63
- Bid/Ask
- $0.41 / $0.41
- Shares Outstanding
- 194.71M
- Market Cap
- $79.38M
- Volume/Avg
- 3M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.95
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 82
- Website
- https://www.luciddx.com
Valuation
Metric | LUCD |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.94 |
Price/Sales | 11.95 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | LUCD |
|---|---|
Quick Ratio | 0.87 |
Current Ratio | 1.20 |
Interest Coverage | −2,872.82 |
Quick Ratio
LUCD
Profitability
Metric | LUCD |
|---|---|
Return on Assets (Normalized) | −116.13% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −127.77% |
Return on Assets
LUCD
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|N%J>l> | LOCK|jf%f> | $181B | |||
| Medtronic PLC MDT | LOCK|Df^>#@m | LOCK|Vvnt | $129B | |||
| Stryker Corp SYK | LOCK|MM@$?@^> | LOCK|cdq | $121B | |||
| Boston Scientific Corp BSX | LOCK|KTm@Hw | LOCK|^J!&G | $63B | |||
| Edwards Lifesciences Corp EW | LOCK|NQS$Bszj | LOCK|X#%c | $61B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|#@n&>H | LOCK|R@ | $38B | |||
| DexCom Inc DXCM | LOCK|V%>d@^t< | LOCK|cxBL | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|G$! | LOCK|%XK | $29B | |||
| Steris PLC STE | LOCK|n^JyD&L | LOCK|?J!C | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|JrF%rrC | LOCK|l&! | $20B |